Active Not RecruitingNCT07223983
Semaglutide after bariatric surgery for alcohol use
About this title
Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)
Read the official source — NCT07223983Medication studyAges 18+United StatesAddiction
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- New HavenSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 26, 2026
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 4
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT07223983
- Official title
Show the full official title
Semaglutide Treatment for Alcohol Use Disorder After Metabolic and Bariatric Surgery: A Pilot Randomized Controlled Trial
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New Haven
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Yale University, a university.
Does this study involve medication?
Yes. The study involves medication, including Semaglutide 1.0 mg.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
